Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial
{{output}}
Objectives: This post-hoc analysis of CM310AD005 conductedaimed to analyze the efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis (AD) with and without prior systemic treatment. ... ...
